Convergent Mechanisms Underlying Reprometabolic Syndrome in Women

This study is looking at how obesity might affect a woman's reproductive hormones. Researchers want to see if obese women respond differently to estradiol patches (a form of estrogen) compared to women with a normal weight. They are specifically measuring the amount of Luteinizing hormone (LH) surge, which is a key hormone in ovulation, after participants wear estradiol patches for 7 days. This study is for women aged 18 to 38 who have regular menstrual cycles. The goal is to understand if obesity causes abnormal responses in the body's hormone control centers. The study's current status is unclear, and it plans to enroll 20 participants.

Study design
This is an open-label study, meaning both you and the study team will know what treatment you are receiving. It involves a small group of 20 women.
What's involved
You would have a screening period of up to 3 weeks, followed by a treatment period of 7-10 days. During treatment, you would wear estradiol patches for up to 7 days, have one blood draw, and collect daily morning urine.
Compensation
Not stated in the trial record.
Follow-up
The primary measurement for the study is taken at the end of the 7-day treatment period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06686537

Convergent Mechanisms Underlying Reprometabolic Syndrome in Women

Recruiting
PHASE2Ages 18–38InterventionalBasic science
University of Colorado, Denver
~20 participants
Updated 2026-07-21 on ClinicalTrials.gov
What's tested:Estradiol Patches

At a glance

Recruiting sites
2 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Amount of Luteinizing hormone Surge
Measured over From enrollment to the end of treatment is 7 days.
Infertility, Female
Obesity
2 sites across 1 states
Colorado2
  • Nanette Santoro, MD · PRINCIPAL_INVESTIGATOR · University of Colorado School of Medicine

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age 18-38
Regular menstrual cycles every 25-35 days
No use of reproductive hormones within the past 3 months
No use of medications interacting with reproductive hormones
Agreement to use reliable barrier contraception or to abstain from intercourse for the duration of the study
Normal thyroid stimulating hormone, prolactin and lipid profiles
No more than 4 hours of moderate to vigorous intensity exercise per week
No history of chronic disease impacting reproductive hormones
No contraindications to administration of estradiol
No history of estrogen dependent cancer
Negative pregnancy test

Exclusion

Has diabetes
Is a smoker
History of venous thromboembolism or known thrombophilia
  • Amount of Luteinizing hormone SurgeFrom enrollment to the end of treatment is 7 days.

    Urinary luteinizing hormone concentration in mIU/mg of Creatinine